Moleculin Biotech Dirección
Dirección controles de criterios 3/4
El CEO de Moleculin Biotech's es Wally Klemp , nombrado en Jul 2015, tiene una permanencia de 8.75 años. compensación anual total es $1.41M, compuesta por 39.9% salario y 60.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.04% de las acciones de la empresa, por valor de $195.56K. La antigüedad media del equipo directivo y de la junta directiva es de 6.8 años y 7.3 años, respectivamente.
Información clave
Wally Klemp
Chief Executive Officer (CEO)
US$1.4m
Compensación total
| Porcentaje del salario del CEO | 39.9% |
| Permanencia del CEO | 8.8yrs |
| Participación del CEO | 2.0% |
| Permanencia media de la dirección | 6.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
May 04Moleculin shares soar after promising Annamycin pre-clinical readout
Feb 02Moleculin Biotech under pressure on reverse stock split
Jan 29Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jan 15Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas
Dec 29Moleculin Bio on go with mid-stage study of Annamycin for lung metastases
Dec 17Moleculin Biotech's annamycin shows encouraging action in animal study
Nov 19Moleculin Biotech EPS beats by $0.04
Nov 13Moleculin further collaborates to advance WP1122 in COVID-19
Oct 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$565k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$2m | US$565k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$2m | US$538k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$15m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$2m | US$500k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$2m | US$625k | -US$13m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$1m | US$403k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$12m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$1m | US$325k | -US$10m |
Compensación vs. Mercado: La compensación total de Wally($USD1.41M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Wally ha sido consistente con los resultados de la empresa en el último año.
CEO
Wally Klemp (63 yo)
8.8yrs
Permanencia
US$1,414,599
Compensación
Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He is President, Chief Executive Officer and Director of Zeno Corporation...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 8.8yrs | US$1.41m | 2.04% $ 213.3k | |
| Executive VP & CFO | 7.8yrs | US$840.64k | 0.24% $ 25.2k | |
| Chief Scientific Officer | 6.8yrs | US$599.11k | 0.27% $ 28.2k | |
| Co-Founder | no data | sin datos | sin datos | |
| Senior Chief Medical Officer | 2.6yrs | sin datos | sin datos | |
| Chief Medical Officer of New Products | 6.5yrs | sin datos | sin datos | |
| European Chief Medical Officer | 2yrs | sin datos | sin datos | |
| Consultant | 6.8yrs | US$69.23k | sin datos | |
| Independent Advisor | no data | US$118.49k | sin datos |
6.8yrs
Permanencia media
68yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MBRX es experimentado (6.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 8.8yrs | US$1.41m | 2.04% $ 213.3k | |
| Co-Founder | no data | sin datos | sin datos | |
| Independent Director | 7.9yrs | US$68.52k | 0% $ 0 | |
| Lead Independent Director | 6.8yrs | US$81.05k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$63.52k | 0% $ 0 | |
| Member of Annamycin Scientific Advisory Board | less than a year | sin datos | sin datos | |
| Independent Director | 7.9yrs | US$74.90k | 0.044% $ 4.6k | |
| Independent Director | 2.2yrs | US$47.15k | 0% $ 0 |
6.8yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de MBRX se considera experimentada (7.3 años de antigüedad promedio).